論文・技術情報追加のお知らせ

1. Postmarketing Safety Signals of Cetuximab and Panitumumab in the FAERS Database: Real-World Insights Focus on Population Heterogeneity.

セツキシマブとパニツムマブの安全性をRWD解析

対象DB：FAERS

2. Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data.

前立腺癌治療ARPIの安全性をRWDで比較解析

対象DB：FAERS,KAERS

3. Sex-Specific Safety Signals of Trelegy Ellipta: A FAERS Pharmacovigilance Analysis.

テリルジーの性差安全性シグナルをFAERS解析で特定

対象DB：FAERS

4. Characteristics and risk factors of serious adverse drug reactions in older patients using the Korea Adverse Event Reporting System data: a retrospective observational study.

高齢者の重篤ADR特性と危険因子を全国データで解析

対象DB：FAERS,KAERS

5. Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network.

C5阻害薬とFcRn阻害薬の安全性と新規シグナルを解析

対象DB：FAERS

6. The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis.

アバコパンのRWD解析で新規副作用シグナルを特定

対象DB：FAERS

7. Integrated pharmacovigilance of fentanyl: multinational analysis reveals novel safety signals and demographic-specific risk profiles.

フェンタニルの多国RWD解析で新規安全性シグナル

対象DB：FAERS,JADER

8. Post-marketing safety profile and clinical prioritization of adverse events with avacopan in ANCA-associated vasculitis: a FAERS pharmacovigilance analysis.

アバコパン使用で肝障害等をRWD解析で特定

対象DB：FAERS

9. Study of epinephrine-induced cardiovascular adverse events in patients with anaphylaxis using two spontaneously reported adverse event databases from 2004 to 2024.

アドレナリン使用で心血管有害事象をRWD解析

対象DB：EudraVigilance,FAERS

10. Safety assessment of Edaravone: A real-world adverse event analysis based on the FAERS Database.

エダラボンの未知の副作用をRWD解析で特定

対象DB：FAERS

11. Systemic Drugs Associated With Maculopathy.

薬剤性黄斑症を全国データで解析し新規薬剤を特定

対象DB：FAERS,KAERS

12. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for cabazitaxel.

カバジタキセル高齢男性で血液毒性重篤傾向

対象DB：FAERS

13. Comparative evaluation of pregnancy-related adverse events associated with proton pump inhibitors using the FDA adverse event reporting system database.

PPI妊娠時AE示唆、薬剤別で早産低体重など差異

対象DB：FAERS

14. Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.

インクレチン薬併用で骨折リスク低減示唆

対象DB：FAERS

15. Real-world safety assessment of tamsulosin based on adverse event analysis from the FAERS database.

タムスロシン初期副作用多発、新規汗過多膀胱炎示唆

対象DB：FAERS

16. Safety evaluation of etrasimod for ulcerative colitis based on the FAERS database.

エトラシモドは消化器・眼毒性や疲労頭痛増加

対象DB：FAERS

17. Real-world safety assessment of ublituximab: a pharmacovigilance analysis based on the FDA adverse event reporting system.

ウブリツキシマブは初期に副作用多く脱毛頭痛も報告

対象DB：FAERS

18. Real-world safety profile of opicapone: a comprehensive pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.

オピカポンは高齢男性で副作用増加、併用注意

対象DB：FAERS

19. Immune checkpoint inhibitor-associated aseptic meningitis: a pharmacovigilance study using the FDA adverse event reporting system (2011-2024).

イピリムマブ併用で無菌性髄膜炎リスク高い

対象DB：FAERS

20. Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database.

FAERSでJAK阻害薬安全性比較

対象DB：FAERS

21. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.

GLP-1作動薬で脱毛報告あり、所見は相反、さらなる検証必要

対象DB：FAERS

22. Text Mining of Symptom Descriptions in the Vaccine Adverse Event Reporting System for Human Papillomavirus Vaccination.

VAERS語彙解析でHPV接種女性の否定的感情強め

対象DB：FAERS,VAERS

23. Hepatobiliary disorders associated with triazole antifungal agents: a disproportionality and Bayesian analysis based on the FAERS database.

TAAsで肝胆系新規有害事象11件、監視強化必要

対象DB：FAERS

24. Psychological Adverse Events and Associated Safety Profiles of Doxepin: A Pharmacovigilance Study Using VigiBase.

ドキセピンで特異AESIなし、薬物乱用シグナルあり

対象DB：VigiBase

25. Preoperative coronary angiography and outcomes in acute type A aortic dissection with coronary malperfusion: A retrospective cohort study.

冠灌流障害合併ATAADでCAG有無で院内死亡差なし

対象DB：DPC

26. Contact Aspiration Combined with a Stent Retriever versus Contact Aspiration Alone in Mechanical Thrombectomy for Acute Ischemic Strokes: A Nationwide Analysis Using the Diagnosis Procedure Combination Database.

CA単独はCA+SRより機能予後良好・死亡率低・費用低

対象DB：DPC

27. Increased Risk of Postoperative Complications in Elderly Hip Fracture Patients With Cognitive Impairment: Evidence From a Japanese Nationwide Database.

認知障害は股関節骨折術後合併症リスク増加、在院延長と薬剤使用低率も示唆

対象DB：DPC

28. The role of visceral fat mass in preserved ratio impaired spirometry (PRISm): The Nagahama study.

PRISmは内臓脂肪と独立に関連し、冠疾患リスク増加

対象DB：JMDC

29. Predicting hypotension, syncope, and fracture risk in patients indicated for antihypertensive treatment: the STRATIFY models.

降圧薬関連の失神・低血圧・骨折リスク予測モデルを開発・検証

対象DB：CPRD

30. Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes.

DPP-4阻害薬等で認知症リスク低下示唆

対象DB：CPRD

31. Economic modelling of providing 'spare' adrenaline autoinjectors to all schools to improve the management of anaphylaxis.

学校に予備AAI配備で費用削減と安全向上

対象DB：CPRD

32. Global Disproportionality Analysis of Adverse Event Reports on Interstitial Lung Diseases for Cancer-Targeted Therapies, 1968-2024.

がん標的抗体でILD亜型の報告シグナル増加

対象DB：KAERS

33. Association of changes in body weight and waist circumference with a subsequent risk of developing hypertension in men requiring specific healthcare guidance.

体重・腹囲の1年減少で高血圧リスク低下

対象DB：DeSC

34. Economic Impact of Self-Injected Biologics for Rheumatoid Arthritis in Japan: A Propensity Score-Matched Analysis From a Public Healthcare Payer Perspective.

自己注射は費用増も受診減で間接節約期待

対象DB：DeSC

35. Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database.

MARTAで膵炎リスク増大、長期使用で発症傾向

対象DB：DeSC